Citations

Showing 10 of 108081 citations.

Impact of bortezomib‐based versus lenalidomide maintenance therapy on outcomes of patients with high‐risk multiple myeloma
Bumma, Naresh , Dhakal, Binod , Fraser, Raphael , Estrada‐Merly, Noel, Freytes, César O. , Hildebrandt, Gerhard , Holmberg, Leona , Krem, Maxwell M. , Lekakis, Lazaros J. , Mian, Hira , Nathan, Sunita , Solh, Melhem , Strouse, Christopher , Vesole, David H. , Kumar, Shaji , Qazilbash, Muzaffar H. , Shah, Nina , Sidana, Surbhi , Holmberg, Leona , Mian, Hira , Nishihori, Taiga , Parrondo, Ricardo D , Kumar, Shaji K , Qazilbash, Muzaffar H , Shah, Nina , D'Souza, Anita , Sidana, Surbhi , Strouse, Christopher S , Dhakal, Binod , Anderson, Kenneth C. , Lee, Cindy , Lazarus, Hillard M. , Murthy, Hemant S. , Nishihori, Taiga , Patel, Sagar S. , D’Souza, Anita

Mayo Clinic

Cancer | April 6, 2023 | Volume: 129 | Issue: 14 | Pages: 2179-2191

10.1002/cncr.34778 | PMID 37021929 Get It

AbstractBackgroundLenalidomide maintenance after autologous stem cell transplant (ASCT) in multiple myeloma (MM) results in superior progression‐free survival and overall survival. However, patients with high‐risk multiple myeloma (HRMM) do not derive the same survival benefit from lenalidomide maintenance compared with standard‐risk patients. The authors sought to determine the outcomes of bortezomib‐based maintenance compared with lenalidomide maintenance in patients with HRMM undergoing ASCT.MethodsIn total, the authors identified 503 patients with HRMM who were undergoing ASCT within 12 months of diagnosis from January 2013 to December 2018 after receiving triplet novel‐agent induction in the Center for International Blood and Marrow Transplant Research database. HRMM was defined as deletion 17p, t(14;16), t(4;14), t(14;20), or chromosome 1q gain.ResultsThree hundred fifty‐seven patients (67%) received lenalidomide alone, and 146 (33%) received bortezomib‐based maintenance (with bortezomib alone in 58%). Patients in the bortezomib‐based maintenance group were more likely to harbor two or more high‐risk abnormalities and International Staging System stage III disease (30% vs. 22%; p = .01) compared with the lenalidomide group (24% vs. 15%; p < .01). Patients who were receiving lenalidomide maintenance had superior progression‐free survival at 2 years compared with those who were receiving either bortezomib monotherapy or combination therapy (75% vs. 63%; p = .009). Overall survival at 2 years was also superior in the lenalidomide group (93% vs. 84%; p = .001).ConclusionsNo superior outcomes were observed in patients with HRMM who received bortezomib monotherapy or (to a lesser extent) in those who received bortezomib in combination as maintenance compared with lenalidomide alone. Until prospective data from randomized clinical trials are available, post‐transplant therapy should be tailored to each patient with consideration for treating patients in clinical trials that target novel therapeutic strategies for HRMM, and lenalidomide should remain a cornerstone of treatment.
Expectations Regarding Gastein Healing Gallery Treatment and Their Connection to Health-Related Quality of Life
Toussaint, Loren , Huynh, Kien, Kohls, Niko , Sirois, Fuschia M. , Alberts, Hannah, Hanshans, Christian , Nguyen, Quang Anh , Offenbäecher, Martin, Sirois, Fuschia , Hanshans, Christian , Toussaint, Loren L , Hirsch, Jameson K. , Zee‐Neuen, Antje van der , Offenbächer, Martin

Mayo Clinic

International Journal of Environmental Research and Public Health | April 6, 2023 | Volume: 20 | Issue: 7 | Pages: 5426

10.3390/ijerph20075426 | PMID 37048040 Get It

The present study examines connections between patient expectations and health-related quality of life. We explore a key distinction between expectations about general health and expectations for functional improvement. Patients were 1444 individuals with multiple conditions experiencing chronic pain who were seeking treatment at the Gastein Healing Gallery in Böckstein, near Bad Gastein, Austria. In addition to measures of expectations, patients completed measures of pain, mental and physical health, life satisfaction, fatigue, and sleep problems. Structural equation models were used to fit a latent variable model where both expectation variables were used to predict health-related quality of life. Results showed that expectations regarding potential functional improvement resulting from treatments at the Gastein Healing Gallery were associated with improved health-related quality of life. Expectations about general health improvements related to treatment were not associated with health-related quality of life. To facilitate optimal healing, clinicians may decide to emphasize expectations about functional recovery when discussing treatment methods similar to those offered at the Gastein Healing Gallery, and in so doing, health-related quality of life may benefit.
Anatomy Versus Physiology: Is Breast Lymphatic Drainage to the Internal Thoracic (Internal Mammary) Lymphatic System Clinically Relevant?
Machado, Priscilla , Liu, Ji‐Bin , Needleman, Laurence , Lee, Christine U. , Forsberg, Flemming , Lee, Christine

Mayo Clinic

Journal of Breast Cancer | April 6, 2023 | Volume: 26 | Issue: 3 | Pages: 286

10.4048/jbc.2023.26.e16 | PMID 37272244 Get It

Improving the process of ordering outside genomic testing for lung cancer FNA and small biopsy specimens – A multidisciplinary quality improvement project
Nokes, Brandon , Baumann, Coralie, Magallanez, Kim, Cartin‐Ceba, Rodrigo , Spiczka, Amy Wendel, Spiczka, Amy Wendel Wendel, Chen, Longwen , Malhotra, Atul

Mayo Clinic

Cytojournal | April 6, 2023 | Volume: 20 | Issue: No issue available | Pages: 8

10.25259/cytojournal_47_2021 | PMID 37151481 Get It

Objectives: Lung cancer is an important cause of mortality in the United States. Targeted mutation analysis has the potential to alter mortality in those with non-small-cell lung cancer. As such, the importance of timely tissue turnaround time (TAT) is substantial. We evaluated TAT at Mayo Clinic Arizona and found it to be delayed relative to national standards. Material and Methods: We conducted a series of plan, do, study, and act (PDSA) cycles at a single institution to identify areas for improvement with our lung cancer genomic testing. We assembled a multidisciplinary team and held serial meetings to discuss data from each PDSA cycle. Results: Using PDSA cycles and multidisciplinary discussions, we were able to identify a number of process limitations slowing TAT. We were then able to generate enhanced and timely communication between providers and pathology, educate and enforce the order/requisition workflow, and establish pathology accessioning with lung cancer specimens top priority. Conclusion: We were able to generate and implement a standard operating procedure for genomic testing of lung cancer specimens at our institution, thereby reducing tissue TAT.
Small Intestinal Bacterial Overgrowth Complicating Gastrointestinal Manifestations of Systemic Sclerosis: A Systematic Review and Meta-analysis
Pakeerathan, Veenaa, Jones, Michael P, Kashyap, Purna , Virgo, Kate, Fairlie, Thomas, Morrison, Mark , Holtmann, Gerald J, Holtmann, Gerald , Jones, Michael , Jones, Michael P , Holtmann, Gerald J , Shah, Ayesha , Jones, Michael P, Ghoshal, Uday C.

Mayo Clinic

Journal of Neurogastroenterology and Motility | April 6, 2023 | Volume: 29 | Issue: 2 | Pages: 132-144

10.5056/jnm22168 | PMID 37019859 Get It

Gender bias in postgraduate year one pharmacy letters of recommendation
Drury, Anna Sahlstrom , Bookstaver, P. Brandon , Hobbs, Brandon , Leung, Jonathan G. , Moon, Jean , Nei, Scott D. , Leung, Jonathan G , Bookstaver, P Brandon , Chang, Kevin, Cook, Aaron M. , Schadler, Aric D. , Witenko, Corey J. , Bissell, Brittany D.

Mayo Clinic

JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY | April 6, 2023 | Volume: 6 | Issue: 5 | Pages: 446-457

10.1002/jac5.1788 Get It

AbstractIntroductionLetters of recommendation (LORs) are important in pharmacy residency applications. Applicant gender, among other variables, may result in implicit biases that could impact LORs and/or residency attainment. This study hypothesized that LORs have linguistic gender differences in pharmacy residency applications.ObjectivesThe primary objective was to determine if gender‐linguistic differences exist in applicants' LORs. Gender was assessed via the pronouns utilized within the applications. The secondary outcome was to assess LOR linguistic and demographic differences between candidates who did and did not receive interviews.MethodsThis was a multiyear, multicenter study involving postgraduate year one (PGY1) applicants to participating pharmacy residency programs. Demographic data were extracted using the PhORCAS (Pharmacy Online Residency Centralized Application Service) WebADMIT (Admissions Management System) portal, and LORs were analyzed by validated linguistics processing software.ResultsA total of 7529 LORs and 2383 applicants (28.5% men, 71.5% women) were included. Women candidates had higher mean number of awards (4.71 vs. 4.1, p = 0.001) and leadership positions (4.87 vs. 4.48, p = 0.019). Compared with men candidates, women had statistically significantly higher levels of clout (p < 0.001), positive emotion (p = 0.01), social processes (p < 0.001), prosocial behavior (p = 0.002), and social referents (p < 0.001). Women also had lower authenticity compared with men candidates (p < 0.001). Two thousand and one hundred twenty applicants included in the secondary analysis found no difference in offer to interview between women and men candidates (odds ratio [OR] 1.173 [95% confidence interval (CI) 0.895–1.57], p = 0.247).ConclusionsMen and women applicants' LORS differed in specific linguistic variables, although offer to interview was not significantly different based on gender. LOR writers and programs should consider implicit biases that could affect residency offers to interview.
The Possibility of Eidetic Memory in a Patient Report of Epileptogenic Zone in Right Temporo-Parietal-Occipital Cortex
Miller, Laura R., Berns, Meaghan, Berry, Brent M, Kucewicz, Michal, Berry, Brent , Kucewicz, Michał T.

Mayo Clinic

Life | April 6, 2023 | Volume: 13 | Issue: 4 | Pages: 956

10.3390/life13040956 | PMID 37109485 Get It

Eidetic memory has been reported in children and in patients with synesthesia but is otherwise thought to be a rare phenomenon. Presented herein is a patient with right-sided language dominance, as proven via multiple functional imaging and neuropsychometric methods, who has a seizure onset zone in the right temporo-parietal-occipital cortex. This patient’s medically refractory epilepsy and thus hyperactive cortex could possibly contribute to near eidetic ability with paired-associates learning tasks (in both short-term and long-term retention). There are reports of epilepsy negatively affecting memory, but as far as the authors are aware to date, there is limited evidence of any lesion enhancing cognitive functions (whether through direct lesion or via compensatory mechanism) that would be localized to a seizure onset zone in the dominant temporo-parietal-occipital junction.
The Cell Biology of Metastatic Invasion in Pancreatic Cancer: Updates and Mechanistic Insights
Joshi, Vidhu B. , Gutierrez-Ruiz, Omar L. , Razidlo, Gina L , Razidlo, Gina L.

Mayo Clinic

Cancers | April 6, 2023 | Volume: 15 | Issue: 7 | Pages: 2169

10.3390/cancers15072169 | PMID 37046830 Get It

Pancreatic ductal adenocarcinoma (PDAC) is one of the leading causes of cancer-related mortality worldwide. This is largely due to the lack of routine screening protocols, an absence of symptoms in early-stage disease leading to late detection, and a paucity of effective treatment options. Critically, the majority of patients either present with metastatic disease or rapidly develop metastatic disease. Thus, there is an urgent need to deepen our understanding of metastasis in PDAC. During metastasis, tumor cells escape from the primary tumor, enter the circulation, and travel to a distant site to form a secondary tumor. In order to accomplish this relatively rare event, tumor cells develop an enhanced ability to detach from the primary tumor, migrate into the surrounding matrix, and invade across the basement membrane. In addition, cancer cells interact with the various cell types and matrix proteins that comprise the tumor microenvironment, with some of these factors working to promote metastasis and others working to suppress it. In PDAC, many of these processes are not well understood. The purpose of this review is to highlight recent advances in the cell biology of the early steps of the metastatic cascade in pancreatic cancer. Specifically, we will examine the regulation of epithelial-to-mesenchymal transition (EMT) in PDAC and its requirement for metastasis, summarize our understanding of how PDAC cells invade and degrade the surrounding matrix, and discuss how migration and adhesion dynamics are regulated in PDAC to optimize cancer cell motility. In addition, the role of the tumor microenvironment in PDAC will also be discussed for each of these invasive processes.
Lifetime Prevalence of Psychiatric Disorders in Adolescents with Unexplained Weight Loss, Underweight, or Poor Appetite
Witte, Micaela A. , Weber, Cynthia Harbeck, Lebow, Jocelyn , Geske, Jennifer R. , Witte, Nathaniel, Whiteside, Stephen P. H. , Loth, Katie A. , Sim, Leslie , Harbeck Weber, Cynthia, Geske, Jennifer, Whiteside, Stephen, Lebow, Jocelyn , Geske, Jennifer , LeMahieu, Allison

Mayo Clinic

Journal of Developmental & Behavioral Pediatrics | April 6, 2023 | Volume: 44 | Issue: 4 | Pages: e277-e283

10.1097/dbp.0000000000001173 | PMID 37020320 Get It

ABSTRACT: Background: When adolescents present with symptoms of unexplained weight loss, underweight, or poor appetite, eating disorders (EDs) are commonly on the list of differential diagnoses. However, the relationship of these symptoms to other psychiatric disorders is often less clear. Methods: Using the Rochester Epidemiology Project database, a retrospective cohort study of adolescents (13–18 years) with billing diagnoses of weight loss, underweight, or loss of appetite was conducted between January 2005 and December 2017. Patients who presented with conditions commonly associated with weight loss, underweight, or poor appetite (e.g., cancer) were excluded. This study sought to examine the proportion of patients who received ED and psychiatric diagnoses within 5 years of the index visit and patient characteristics associated with these diagnoses. Results: Of 884 patients diagnosed with symptoms of unexplained weight loss, underweight, or poor appetite, 662 patients (M age = 15.8; SD = 1.6; 66.0% female) met study criteria. Within 5 years of the index visit, the lifetime prevalence of all psychiatric disorders was 70% (n = 461) and of EDs was 21% (n = 141). For both psychiatric disorders and EDs, sex and race were significantly associated with receiving a diagnosis within 5 years. Decrease in body mass index (BMI) percentile was associated with receiving an ED diagnosis, whereas the highest historical BMI percentile was associated with receiving a psychiatric diagnosis. Conclusion: Patients presenting with symptoms of unexplained weight loss, underweight, or poor appetite are at risk not only for EDs but also for other psychiatric disorders that may require further assessment and follow-up.
Outcomes of Patients With Classic Hodgkin Lymphoma Who Relapsed After Autologous Stem Cell Transplant
Matin, Aasiya , Inwards, David J. , Micallef, Ivana N. , Johnston, Patrick B. , Porrata, Luis F. , Nowakowski, Grzegorz S. , Ansell, Stephen M. , Micallef, Ivana, Porrata, Luis, Tun, Aung M. , Wang, Yucai , Habermann, Thomas M. , Paludo, Jonas , Villasboas, José C. , Rosenthal, Allison , Tun, Han W. , Cerhan, James R. , Witzig, Thomas E.

Mayo Clinic

HemaSphere | April 5, 2023 | Volume: 7 | Issue: 4 | Pages: e869

10.1097/hs9.0000000000000869 | PMID 37034004 Get It

Immune checkpoint inhibitors (ICIs) and brentuximab vedotin (BV) are novel agents for classic Hodgkin lymphoma, including relapse after autologous stem cell transplant (ASCT). However, their impact on survival post-ASCT relapse, in comparison with conventional therapy, is less known due to the lack of randomized controlled trials. Clinical characteristics and outcomes of 115 patients with relapse (or progression) after ASCT are studied. After a median follow-up of 8.59 years from post-ASCT relapse, the median progression-free survival (PFS) and overall survival (OS) were 0.91 and 5.07 years, respectively. Median lines of therapy after post-ASCT relapse was 2 (range, 1–12). The median PFS was not reached (NR) versus 1.11 versus 0.50 versus 0.85 versus 0.78 years (P = 0.006) and OS was NR versus 7.60 versus 3.08 versus 3.51 versus 3.17 years (P = 0.28) in patients first treated with ICIs versus BV versus investigational agents versus chemotherapy versus radiation therapy (RT). First-line treatment with novel agents (ie, ICIs and BV) was associated with superior outcomes compared with investigational agents and chemotherapy/RT with a median PFS of 1.65 versus 0.50 versus 0.79 years (P = 0.003) and a median OS of 7.60 versus 3.08 versus 3.32 years (P = 0.08). Regardless of lines of therapy, the treatment with ICIs had the most favorable outcome with a median PFS and OS of 3.98 and NR years, respectively. Allogeneic stem cell transplant (allo-SCT) was done in 23 patients (20%), and the median post-allo-SCT PFS and OS were 1.31 and 2.35 years, respectively. In conclusion, survival following post-ASCT relapse improves significantly when patients receive novel agents.